Thank you for subscribing!
Finfeed Archived Sep 10, 2020
The TGA has recommended that CBD products be down-scheduled to schedule 3 medicines in Australia, allowing OTC sales, which should benefit Creso Pharma (ASX: CPH).
Get expert stock analysis direct in your inbox
Join Our Mailing List